Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven

doi:10.5306/wjco.v16.i9.106646

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (164)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=61

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=78

Sep 24, 2025 (publication date) through Oct 1, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Sep 24, 2025; 16(9): 106646
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.106646

Open in New Tab Full Size Figure Download Figure

Figure 1 A classification of antibody-drug conjugates based on their target antigens and cytotoxic payloads. The antibody-drug conjugates (ADCs) are categorized according to their antigen specificity, including anti-NECTIN4, anti-HER2, anti-B7-H3, anti-TROP2, and anti-DLL3. Each ADC is listed alongside its corresponding payload, which is color-coded according to its mechanism of action: Microtubule inhibitors, topoisomerase I inhibitors (Dxd, SN-38), and DNA crosslinking agents. MMAE: Monomethyl auristatin E; Dxd: Deruxtecan; PBD: Pyrrolobenzodiazepine.

Citation: D’Angelo A, Catalano M, De Gennaro Aquino I, Gangi V, Roviello G. Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven. World J Clin Oncol 2025; 16(9): 106646
URL: https://www.wjgnet.com/2218-4333/full/v16/i9/106646.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i9.106646